Bornstein et al. recently published a consensus statement on the management of diabetes with COVID‐19 and suggested that there could be an increase in Diabetic Ketoacidosis (DKA) in type 1 diabetes (T1DM) and type 2 diabetes (T2DM) on sodium glucose cotransporter inhibitors (SGLT2). Here, SLC5A2 is linked to type 2 diabetes mellitus.